On December 30th, 2017, Resolution of the Cabinet of Ministers of Ukraine No. 1081 dated December 13 th, 2017 came into force and approved the new edition of the National List.
The updated National List includes 427 INNs.
The project has been developed in accordance with the recently adopted amendments to the Regulations on the National List of Essential Medicines and the Regulations on the Expert Committee on the Selection and Use of Essential Medicines, which has been mentioned here.
Thus, the Expert Committee on the Selection and Use of Essential Medicines conducted an analysis of clinical efficacy and safety of medicinal products confirmed by evidence-based medicine (without pharmacoeconomic analysis) recommended for inclusion in the National List of Essential Medicines following the "fast-track" procedure. As a result of such work, it is proposed to supplement the National List with the following drugs:
The National List in the revised edition will become the basis for public procurement in 2018.
Subsequently, the National List will be supplemented by new positions based on applications of individuals and legal entities, in particular, holders of registration certificates, on the results of their consideration by the Expert Committee. Applications are accepted throughout the calendar year.
Previously, these issues were actively discussed during the Conference "Healthcare And Pharmaceuticals - 2018. Anticipations And Expectations", held on December 13-14 in Kyiv.
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.